Peginesatide, Omontys*, for treatment of anemia in adult dialysis patients

Peginesatide, is a stimulant of erythropoiesis as erythropoietin but it is different by its structure, it consists of two peptide chains bound chemically and pegylated. It is not genetically engineered. Peginesatide obtained from the FDA , March 27, 2012, its approval as Omontys* for the treatment of anemia in adult dialysis patients who have chronic kidney disease. It has the advantage of requiring only 1 subcutaneous injection per month. Omontys* seems as safe and effective as epoetin but a longer duration of observation is necessary to confirm these results.

Erythropoietin is marketed as epoetin alfa and darbepoetin alfa